{"id":4670,"date":"2016-08-04T00:00:00","date_gmt":"2016-08-04T06:00:00","guid":{"rendered":"https:\/\/www.uchealth.org\/today\/2016\/08\/04\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\/"},"modified":"2021-08-03T09:28:24","modified_gmt":"2021-08-03T15:28:24","slug":"promising-alzheimer-drug-study-set-to-kick-off-at-uch","status":"publish","type":"post","link":"https:\/\/www.uchealth.org\/today\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\/","title":{"rendered":"Promising Alzheimer drug study set to kick off at UCH"},"content":{"rendered":"
<\/div>
\"\"
The Rocky Mountain Alzhiemer’s Disease Center team leading the leukine work includes, from left, Jonathan Woodcock, MD, Tim Boyd, PhD, and Huntington Potter, PhD, who leads the center.<\/figcaption><\/figure>\n

More than six years after reporting on<\/a> their discovery of the striking effects a cancer-recovery drug has on mice with Alzheimer\u2019s disease, Huntington Potter<\/a> and Tim Boyd finally have the opportunity to test its long-term impact on real patients. A two-year, $1 million grant<\/a> from the Alzheimer\u2019s Association, announced on Aug. 3, is paving the way.<\/p>\n

Potter and Boyd are PhD scientists with the Rocky Mountain Alzheimer\u2019s Disease Center (RMADC<\/a>) at the University of Colorado, which Potter leads. The drug is called Leukine, and in the research that led to the discovery published in 2010, they and colleagues found that Leukine spurred the Alzheimer\u2019s mice to clear their brains of 55 percent of disease-associated amyloid beta plaques \u2013 and that the mice\u2019s cognition returned to normal.<\/p>\n

Leukine is a growth factor protein. The U.S. Food and Drug Administration approved it in 1995 to stimulate the production of white blood cells and fortify the weakened immune systems of bone marrow transplant patients. In the case of the Alzheimer\u2019s mice, the white blood cells attacked and cleared out the amyloid plaques. But also, Boyd says, Leukine \u201chas been known in models of stroke to regrow blood vessels. It prevents neurons around an infarct from dying, and is a growth factor for neural stem cells.\u201d<\/p>\n

And indeed, that\u2019s what may have happened with the mice. Potter’s laboratory is investigating whether Leukine stimulates the development of new blood vessels and brain cells to fill the voids the plaque had left behind. If the same thing happens in human patients, it could address a big problem with other experimental drugs that clear out amyloid beta plaques without addressing the voids. Those gaps lead to serious problems, including swelling in the brain and \u00a0microhemorrhaging, that have been so common<\/a> among other experimental amyloid beta-reducing therapies that they have their own acronym: ARIA, for amyloid-related imaging abnormalities.<\/p>\n

Testing, testing<\/strong><\/p>\n

The new trial, slated to start in October, will involve 42 patients with mild to moderate Alzheimer\u2019s disease. Twenty-eight will receive daily Leukine injections for six months, while 14 will get a placebo over the same period. The team decided to give the drug to more than the typical one-half of the cohort because, as Potter put it, \u201cit\u2019s much nicer to be recruited into a clinical trial that lasts that long when you have a two-thirds chance of getting the drug.\u201d<\/p>\n

The RMADC team will perform many tests on participants during those six months and for 45 days after the treatment course ends. They\u2019ll check on the brain\u2019s use of glucose (Alzheimer\u2019s disease slows consumption of this brain fuel); do PET scans to check on Leukine-driven removal of amyloid beta plaque; and do MRIs to see if the brain is decreasing in size or not (Alzheimer\u2019s disease shrinks the brain) and to check on ARIA-related edema and microhemorrhaging. They\u2019ll also perform standard blood tests and electrocardiograms to make sure the immunologic reaction to Leukine isn\u2019t causing damage to the heart or elsewhere in the body.<\/p>\n

Much of the testing will fall to Jonathan Woodcock, MD<\/a>, clinical director of the RMADC and the Memory Disorders Clinic at University of Colorado Hospital. Woodcock will also help recruit patients via the clinic. In addition, Brianne Bettcher, PhD<\/a>, who leads the RMADC\u2019s neuropsychology research team, will perform cognitive assessments on patients.<\/p>\n

Potter\u2019s is one of four research teams \u2013 the others are in California, Florida and Spain \u2013 receiving $1 million awards through a $7 million grant fueled by an Alzheimer\u2019s Association partnership with Silicon Valley philanthropist Michaela \u201cMickey\u201d Hoag. The team with the most compelling results will get the final $3 million to continue their investigations.<\/p>\n

Years of prep<\/strong><\/p>\n

Potter and Boyd have been laying the groundwork for the new Leukine trial for years. They studied<\/a> the cognition of bone marrow transplant patients who had taken Leukine for the standard three-week course of injections. They found that, six months later, such patients showed \u201csignificantly greater improvement in total neuropsychological function\u201d than those treated with a different immune-system booster, and they performed better than they had in baseline testing, too.<\/p>\n

\u201cIt had nothing to do with Alzheimer\u2019s disease or amyloid,\u201d Potter said. \u201cSo there may be a general benefit.\u201d<\/p>\n

In 2014, Potter and Woodcock launched<\/a> a trial to assess the safety of Leukine in Alzheimer\u2019s patients taking the drug for three weeks \u2013 the standard course for bone marrow transplant patients. Woodcock says nothing they\u2019ve seen in the roughly dozen patients who have participated contradicts the drug\u2019s 21-year history of safety.<\/p>\n

Alzheimer\u2019s, a disease afflicting 5.5 million people in the United States, has a long history of leaving promising therapies broken under its wheels. Potter, Boyd and Woodcock, keenly aware of this, will let Leukine succeed or fail with Alzheimer\u2019s patients and report what they find. Still, they are hopeful.<\/p>\n

\u201cWe\u2019re a little prejudiced, but it has many benefits that no other drug has,\u201d Potter said.<\/p>\n

For more information on participating in the Leukine phase 2 clinical trial, register via the Alzheimer\u2019s Association\u2019s<\/em> TrialMatch program<\/em><\/a> or call (800) 272-3900.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

More than six years after reporting on their discovery of the striking effects a cancer-recovery drug has on mice with Alzheimer\u2019s disease, Huntington Potter and Tim Boyd finally have the opportunity to test its long-term impact on real patients. A two-year, $1 million grant from the Alzheimer\u2019s Association, announced on Aug. 3, is paving the […]<\/p>\n","protected":false},"author":23,"featured_media":8304,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[5],"tags":[185,4781],"class_list":["post-4670","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-innovative-care","tag-alzheimers-care","tag-research-in-health-care"],"acf":[],"yoast_head":"\nPromising Alzheimer drug study set to kick off at UCH - UCHealth Today<\/title>\n<meta name=\"description\" content=\"More than six years after reporting on their discovery of the striking effects a cancer-recovery drug has on mice with Alzheimer\u2019s disease, Huntington Potter and Tim Boyd finally have the opportunity to test its long-term impact on real patients. A two-year, $1 million grant fr...\" \/>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Promising Alzheimer drug study set to kick off at UCH\" \/>\n<meta property=\"og:description\" content=\"More than six years after reporting on their discovery of the striking effects a cancer-recovery drug has on mice with Alzheimer\u2019s disease, Huntington Potter and Tim Boyd finally have the opportunity to test its long-term impact on real patients. A two-year, $1 million grant from the Alzheimer\u2019s Association, announced on Aug. 3, is paving the […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.uchealth.org\/today\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\/\" \/>\n<meta property=\"og:site_name\" content=\"UCHealth Today\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/uchealthorg\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-08-04T06:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-08-03T15:28:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2016\/08\/28140531\/EXT_080416_WoodcockBoydPotter.jpg\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Todd Neff, for UCHealth\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@uchealth\" \/>\n<meta name=\"twitter:site\" content=\"@uchealth\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Todd Neff, for UCHealth\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\\\/\"},\"author\":{\"name\":\"Todd Neff, for UCHealth\",\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/#\\\/schema\\\/person\\\/da7733ff5562e48e55c027d111ee5911\"},\"headline\":\"Promising Alzheimer drug study set to kick off at UCH\",\"datePublished\":\"2016-08-04T06:00:00+00:00\",\"dateModified\":\"2021-08-03T15:28:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\\\/\"},\"wordCount\":894,\"publisher\":{\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/uchealth-wp-uploads.s3.amazonaws.com\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2016\\\/08\\\/28140531\\\/EXT_080416_WoodcockBoydPotter.webp\",\"keywords\":[\"Alzheimer's care\",\"Research in health care\"],\"articleSection\":[\"Innovative care\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\\\/\",\"url\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\\\/\",\"name\":\"Promising Alzheimer drug study set to kick off at UCH - UCHealth Today\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/uchealth-wp-uploads.s3.amazonaws.com\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2016\\\/08\\\/28140531\\\/EXT_080416_WoodcockBoydPotter.webp\",\"datePublished\":\"2016-08-04T06:00:00+00:00\",\"dateModified\":\"2021-08-03T15:28:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.uchealth.org\\\/today\\\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\\\/#primaryimage\",\"url\":\"https:\\\/\\\/uchealth-wp-uploads.s3.amazonaws.com\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2016\\\/08\\\/28140531\\\/EXT_080416_WoodcockBoydPotter.webp\",\"contentUrl\":\"https:\\\/\\\/uchealth-wp-uploads.s3.amazonaws.com\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2016\\\/08\\\/28140531\\\/EXT_080416_WoodcockBoydPotter.webp\",\"width\":1200,\"height\":800,\"caption\":\"The Rocky Mountain Alzhiemer's Disease Center team leading the leukine work includes, from left, Jonathan Woodcock, MD, Tim Boyd, PhD, and Huntington Potter, PhD, who leads the center.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Promising Alzheimer drug study set to kick off at UCH\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/#website\",\"url\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/\",\"name\":\"UCHealth Today\",\"description\":\"UCHealth Today\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/#organization\",\"name\":\"UCHealth\",\"url\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/uchealth-wp-uploads.s3.amazonaws.com\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2020\\\/04\\\/24135149\\\/UCHealth-square-logo-1000x1000-1.jpg\",\"contentUrl\":\"https:\\\/\\\/uchealth-wp-uploads.s3.amazonaws.com\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2020\\\/04\\\/24135149\\\/UCHealth-square-logo-1000x1000-1.jpg\",\"width\":1000,\"height\":1000,\"caption\":\"UCHealth\"},\"image\":{\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/uchealthorg\\\/\",\"https:\\\/\\\/x.com\\\/uchealth\",\"https:\\\/\\\/www.instagram.com\\\/uchealth\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/school\\\/14839\\\/\",\"https:\\\/\\\/www.pinterest.com\\\/uchealthorg\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UC41SJI79yjZIe96OajzN22g\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/#\\\/schema\\\/person\\\/da7733ff5562e48e55c027d111ee5911\",\"name\":\"Todd Neff, for UCHealth\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ba17a8f1358d39c104ff6cb59da7fe21b9bfc792948447c3ac964e93b37aa49f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ba17a8f1358d39c104ff6cb59da7fe21b9bfc792948447c3ac964e93b37aa49f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ba17a8f1358d39c104ff6cb59da7fe21b9bfc792948447c3ac964e93b37aa49f?s=96&d=mm&r=g\",\"caption\":\"Todd Neff, for UCHealth\"},\"description\":\"Todd Neff has written hundreds of stories for University of Colorado Hospital and UCHealth. He covered science and the environment for the Daily Camera in Boulder, Colorado, and has taught narrative nonfiction at the University of Colorado, where he was a Ted Scripps Fellowship recipient in Environmental Journalism. He is author of \u201cA Beard Cut Short,\u201d a biography of a remarkable professor; \u201cThe Laser That\u2019s Changing the World,\u201d a history of lidar; and \u201cFrom Jars to the Stars,\u201d a history of Ball Aerospace.\",\"url\":\"https:\\\/\\\/www.uchealth.org\\\/today\\\/author\\\/tneff\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Promising Alzheimer drug study set to kick off at UCH - UCHealth Today","description":"More than six years after reporting on their discovery of the striking effects a cancer-recovery drug has on mice with Alzheimer\u2019s disease, Huntington Potter and Tim Boyd finally have the opportunity to test its long-term impact on real patients. A two-year, $1 million grant fr...","robots":{"index":"noindex","follow":"follow"},"og_locale":"en_US","og_type":"article","og_title":"Promising Alzheimer drug study set to kick off at UCH","og_description":"More than six years after reporting on their discovery of the striking effects a cancer-recovery drug has on mice with Alzheimer\u2019s disease, Huntington Potter and Tim Boyd finally have the opportunity to test its long-term impact on real patients. A two-year, $1 million grant from the Alzheimer\u2019s Association, announced on Aug. 3, is paving the […]","og_url":"https:\/\/www.uchealth.org\/today\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\/","og_site_name":"UCHealth Today","article_publisher":"https:\/\/www.facebook.com\/uchealthorg\/","article_published_time":"2016-08-04T06:00:00+00:00","article_modified_time":"2021-08-03T15:28:24+00:00","og_image":[{"url":"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2016\/08\/28140531\/EXT_080416_WoodcockBoydPotter.jpg","type":"image\/jpeg"}],"author":"Todd Neff, for UCHealth","twitter_card":"summary_large_image","twitter_creator":"@uchealth","twitter_site":"@uchealth","twitter_misc":{"Written by":"Todd Neff, for UCHealth","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.uchealth.org\/today\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\/#article","isPartOf":{"@id":"https:\/\/www.uchealth.org\/today\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\/"},"author":{"name":"Todd Neff, for UCHealth","@id":"https:\/\/www.uchealth.org\/today\/#\/schema\/person\/da7733ff5562e48e55c027d111ee5911"},"headline":"Promising Alzheimer drug study set to kick off at UCH","datePublished":"2016-08-04T06:00:00+00:00","dateModified":"2021-08-03T15:28:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.uchealth.org\/today\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\/"},"wordCount":894,"publisher":{"@id":"https:\/\/www.uchealth.org\/today\/#organization"},"image":{"@id":"https:\/\/www.uchealth.org\/today\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\/#primaryimage"},"thumbnailUrl":"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2016\/08\/28140531\/EXT_080416_WoodcockBoydPotter.webp","keywords":["Alzheimer's care","Research in health care"],"articleSection":["Innovative care"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.uchealth.org\/today\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\/","url":"https:\/\/www.uchealth.org\/today\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\/","name":"Promising Alzheimer drug study set to kick off at UCH - UCHealth Today","isPartOf":{"@id":"https:\/\/www.uchealth.org\/today\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.uchealth.org\/today\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\/#primaryimage"},"image":{"@id":"https:\/\/www.uchealth.org\/today\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\/#primaryimage"},"thumbnailUrl":"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2016\/08\/28140531\/EXT_080416_WoodcockBoydPotter.webp","datePublished":"2016-08-04T06:00:00+00:00","dateModified":"2021-08-03T15:28:24+00:00","breadcrumb":{"@id":"https:\/\/www.uchealth.org\/today\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.uchealth.org\/today\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.uchealth.org\/today\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\/#primaryimage","url":"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2016\/08\/28140531\/EXT_080416_WoodcockBoydPotter.webp","contentUrl":"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2016\/08\/28140531\/EXT_080416_WoodcockBoydPotter.webp","width":1200,"height":800,"caption":"The Rocky Mountain Alzhiemer's Disease Center team leading the leukine work includes, from left, Jonathan Woodcock, MD, Tim Boyd, PhD, and Huntington Potter, PhD, who leads the center."},{"@type":"BreadcrumbList","@id":"https:\/\/www.uchealth.org\/today\/promising-alzheimer-drug-study-set-to-kick-off-at-uch\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.uchealth.org\/today\/"},{"@type":"ListItem","position":2,"name":"Promising Alzheimer drug study set to kick off at UCH"}]},{"@type":"WebSite","@id":"https:\/\/www.uchealth.org\/today\/#website","url":"https:\/\/www.uchealth.org\/today\/","name":"UCHealth Today","description":"UCHealth Today","publisher":{"@id":"https:\/\/www.uchealth.org\/today\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.uchealth.org\/today\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.uchealth.org\/today\/#organization","name":"UCHealth","url":"https:\/\/www.uchealth.org\/today\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.uchealth.org\/today\/#\/schema\/logo\/image\/","url":"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2020\/04\/24135149\/UCHealth-square-logo-1000x1000-1.jpg","contentUrl":"https:\/\/uchealth-wp-uploads.s3.amazonaws.com\/wp-content\/uploads\/sites\/6\/2020\/04\/24135149\/UCHealth-square-logo-1000x1000-1.jpg","width":1000,"height":1000,"caption":"UCHealth"},"image":{"@id":"https:\/\/www.uchealth.org\/today\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/uchealthorg\/","https:\/\/x.com\/uchealth","https:\/\/www.instagram.com\/uchealth\/","https:\/\/www.linkedin.com\/school\/14839\/","https:\/\/www.pinterest.com\/uchealthorg\/","https:\/\/www.youtube.com\/channel\/UC41SJI79yjZIe96OajzN22g"]},{"@type":"Person","@id":"https:\/\/www.uchealth.org\/today\/#\/schema\/person\/da7733ff5562e48e55c027d111ee5911","name":"Todd Neff, for UCHealth","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/ba17a8f1358d39c104ff6cb59da7fe21b9bfc792948447c3ac964e93b37aa49f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ba17a8f1358d39c104ff6cb59da7fe21b9bfc792948447c3ac964e93b37aa49f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba17a8f1358d39c104ff6cb59da7fe21b9bfc792948447c3ac964e93b37aa49f?s=96&d=mm&r=g","caption":"Todd Neff, for UCHealth"},"description":"Todd Neff has written hundreds of stories for University of Colorado Hospital and UCHealth. He covered science and the environment for the Daily Camera in Boulder, Colorado, and has taught narrative nonfiction at the University of Colorado, where he was a Ted Scripps Fellowship recipient in Environmental Journalism. He is author of \u201cA Beard Cut Short,\u201d a biography of a remarkable professor; \u201cThe Laser That\u2019s Changing the World,\u201d a history of lidar; and \u201cFrom Jars to the Stars,\u201d a history of Ball Aerospace.","url":"https:\/\/www.uchealth.org\/today\/author\/tneff\/"}]}},"coauthors":[{"id":23,"name":"Todd Neff","link":"https:\/\/www.uchealth.org\/today\/author\/tneff\/"}],"_links":{"self":[{"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/posts\/4670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/comments?post=4670"}],"version-history":[{"count":10,"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/posts\/4670\/revisions"}],"predecessor-version":[{"id":35030,"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/posts\/4670\/revisions\/35030"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/media\/8304"}],"wp:attachment":[{"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/media?parent=4670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/categories?post=4670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.uchealth.org\/today\/wp-json\/wp\/v2\/tags?post=4670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}